De Mello Walmor C, Gerena Yamil
Department of Pharmacology, School of Medicine, Medical Sciences Campus, UPR, San Juan, PR 00936-5067, USA.
Regul Pept. 2008 Nov 29;151(1-3):54-60. doi: 10.1016/j.regpep.2008.06.003. Epub 2008 Jun 8.
The influence of chronic administration of eplerenone on the intracrine as well as on the extracellular action of angiotensin II (Ang II) on L-type inward calcium current was investigated in the failing heart of cardiomyopathic hamsters (TO-2).For this, eplerenone (200 mg/kg/day) was administered orally to 2 month-old cardiomyopathic hamsters for a period of 3 months. Measurements of the peak inward calcium current (I(Ca)) was performed in single cells under voltage clamp using the whole cell configuration. The results indicated that eplerenone suppressed the intracrine action of Ang II (10(-)(8) M) on peak I(Ca) density. Moreover, the intracellular dialysis of the peptide did not change the time course of I(Ca) inactivation in animals treated chronically with eplerenone. The extracellular administration of Ang II (10(-)(8) M) incremented the peak I(Ca) density by only 20+/-8% (n=30) compared with 38+/-4% (n=35) (P<0.05) obtained in age-matched cardiomyopathic hamsters not exposed to eplerenone. Interestingly, the inhibitory of eplerenone (10(-7) M) on the intracrine action of Ang II was also found, in vitro, but required an incubation period of, at least, 24 h. The inhibitory action of eplerenone on the intracellular action of Ang II was partially reversed by exposing the eplerenone-treated cells to aldosterone (10 nM) for a period of 24 h what supports the view that: a) the mineralocorticoid receptor(MR) was involved in the modulation of the intracrine action of the peptide; b) the effect of eplerenone on the intracrine as well as on the extracellular action of Ang II was related ,in part, to a decreased expression of membrane-bound and intracellular AT1 receptors.
a) eplerenone inhibits the intracrine action of Ang II on inward calcium current and reduces drastically the effect of extracellular Ang II on I(Ca); b) aldosterone is able to revert the effect of eplerenone; c) the mineralocorticoid receptor is an essential component of the intracrine renin angiotensin aldosterone system.
研究了依普利酮长期给药对血管紧张素II(Ang II)在扩张型心肌病仓鼠(TO-2)衰竭心脏中对L型内向钙电流的内分泌及细胞外作用的影响。为此,对2月龄的扩张型心肌病仓鼠口服依普利酮(200 mg/kg/天),持续3个月。使用全细胞模式在电压钳制下对单个细胞进行内向钙电流峰值(I(Ca))测量。结果表明,依普利酮抑制了Ang II(10(-8) M)对I(Ca)密度的内分泌作用。此外,在长期接受依普利酮治疗的动物中,该肽的细胞内透析并未改变I(Ca)失活的时间进程。与未接触依普利酮的年龄匹配的扩张型心肌病仓鼠相比,细胞外给予Ang II(10(-8) M)使I(Ca)密度峰值仅增加20±8%(n = 30),而未接触依普利酮的仓鼠增加38±4%(n = 35)(P < 0.05)。有趣的是,在体外也发现依普利酮(10(-7) M)对Ang II的内分泌作用有抑制作用,但至少需要24小时的孵育期。将依普利酮处理的细胞暴露于醛固酮(10 nM)24小时后,依普利酮对Ang II细胞内作用的抑制作用部分逆转,这支持了以下观点:a)盐皮质激素受体(MR)参与了该肽内分泌作用的调节;b)依普利酮对Ang II内分泌及细胞外作用的影响部分与膜结合和细胞内AT1受体表达降低有关。
a)依普利酮抑制Ang II对内向钙电流的内分泌作用,并显著降低细胞外Ang II对I(Ca)的作用;b)醛固酮能够逆转依普利酮的作用;c)盐皮质激素受体是内分泌肾素-血管紧张素-醛固酮系统的重要组成部分。